Summary
19KA Chart
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.
CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating
CorMedix delivered strong Q3 results, with DefenCath outperforming expectations and near-term earnings power underestimated in prior analysis. CRMD raised FY25 guidance, but long-term risks remain due to TDAPA reimbursement changes, pricing pressure, and customer concentration. The Melinta acquisition and Rezzayo prophylaxis trial offer growth optionality, but Rezzayo's success is uncertain and pivotal for post-TDAPA prospects.
Wall Street Analysts Predict an 80.58% Upside in CorMedix (CRMD): Here's What You Should Know
The mean of analysts' price targets for CorMedix (CRMD) points to an 80.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CorMedix Inc. (19KA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CorMedix Inc. ever had a stock split?
CorMedix Inc. Profile
| - Industry | - Sector | Joseph Todisco MBA CEO | XSTU Exchange | US21900C3088 ISIN |
| US Country | 64 Employees | - Last Dividend | 26 Mar 2019 Last Split | 25 Mar 2010 IPO Date |
Overview
CorMedix Inc. is a biopharmaceutical company committed to the development and commercialization of novel therapeutic products aimed at the prevention and treatment of infectious and inflammatory diseases, primarily in the United States. Originally founded as Picton Holding Company, Inc., the organization underwent a name change to CorMedix Inc. in January 2007, symbolizing a focused shift towards its core mission in the biopharmaceutical arena. Incorporated in 2006, CorMedix has established its operational base in Berkeley Heights, New Jersey, from where it spearheads its research, development, and commercialization efforts. The company's strategic initiatives are directed towards addressing the unmet medical needs of patients, particularly those suffering from kidney failure, through innovative solutions designed to enhance patient care and outcomes.
Products and Services
CorMedix Inc. is actively involved in the development and prospective commercialization of a leading product candidate, alongside engagement in research aimed at expanding its product portfolio. Detailed below are the key focus areas of its product development efforts:
- DefenCath: CorMedix's flagship product candidate, DefenCath, is an antimicrobial catheter lock solution designed to significantly reduce the incidence of catheter-related bloodstream infections among adult patients with kidney failure. This innovative solution represents a proactive approach to healthcare, aiming to improve patient outcomes and quality of life by combating the challenges posed by bloodstream infections, which are a common complication in patients undergoing dialysis treatments.
Contact Information
